First Eagle Investment Management LLC Acquires 93,553 Shares of Haleon plc (NYSE:HLN)

First Eagle Investment Management LLC boosted its holdings in Haleon plc (NYSE:HLN - Free Report) by 4.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,104,289 shares of the company's stock after buying an additional 93,553 shares during the quarter. First Eagle Investment Management LLC's holdings in Haleon were worth $20,075,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Sierra Ocean LLC purchased a new position in Haleon in the 4th quarter worth about $26,000. Versant Capital Management Inc raised its position in Haleon by 2,029.1% in the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company's stock worth $34,000 after buying an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in Haleon in the 4th quarter worth about $35,000. Toronto Dominion Bank raised its position in Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company's stock worth $38,000 after buying an additional 3,470 shares during the last quarter. Finally, Spire Wealth Management purchased a new position in Haleon in the 4th quarter worth about $39,000. Hedge funds and other institutional investors own 6.67% of the company's stock.

Analyst Ratings Changes

A number of brokerages have weighed in on HLN. Morgan Stanley lowered Haleon from an "overweight" rating to an "equal weight" rating in a research report on Friday, January 10th. HSBC reaffirmed a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Sanford C. Bernstein lowered shares of Haleon from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 8th. Hsbc Global Res lowered shares of Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Six investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $10.95.

Remove Ads

Haleon Stock Performance

Haleon stock traded down $0.02 during midday trading on Tuesday, hitting $10.30. The stock had a trading volume of 18,811,650 shares, compared to its average volume of 6,696,057. The firm's fifty day moving average is $9.77 and its two-hundred day moving average is $9.88. The company has a market capitalization of $46.61 billion, a PE ratio of 30.28, a P/E/G ratio of 2.82 and a beta of 0.25. Haleon plc has a 52-week low of $7.89 and a 52-week high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. On average, research analysts forecast that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The company also recently announced a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a $0.1166 dividend. This represents a yield of 1.6%. This is a positive change from Haleon's previous -- dividend of $0.05. The ex-dividend date of this dividend is Friday, April 25th. Haleon's dividend payout ratio is currently 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.